Characteristic of Past Deals:
Portfolio Diversification In Life Science Strategy
-Total number of companies advisory and or investment: 48
-Top 6 companies invested in accounted for $900 million of capital deployed, some 56% of the total investment portfolio or a 5 year period
-Remaining 42 companies averaged some $21 million each
US companies comprised 70% of the portfolio by investment amount; 60% by number
15 non-US companies from 12 different countries: Israel, Netherlands, UK, Ireland, China, Caiman Island, Brazil, Canada, Mexico, Spain, Italy. Investment returns were similar across nationalities.
Underlying Asset Scientific Breakdown:
-Therapeutics comprised some 85% by volume of investment, with medical device companies the remainder. There were a total of 30 lead research areas/indications across the companies advised and invested in.